Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGT007 in Relapsed/Metastatic Nasopharyngeal Carcinoma
NCT05616468Phase 1Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Dec 2022
- Primary completion
- Dec 2024
- Modality
- Prophylactic Vaccines, CAR-T Cells, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BGT007 in nasopharyngeal carcinoma (NPC), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Dose-limiting toxicity. Started Dec 2022; status: recruiting.
02
Drugs
BGT007
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05616468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05616468.